Abstract
Background: Despite trials with new compounds, survival rates for sarcoma patients have stagnated over the past 20 years. Subcutaneous implanted patient-derived xenografts (PDX) are used to validate preclinical research, however they do not tend to recapitulate the heterogeneity of the tumour nor have the propensity to metastasize. This discrepancy between preclinical models and the clinical course of sarcoma patients is a possible rationale why clinical translation is still absent. There is a great need for PDX that accurately represents the patient’s clinical course.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
